Liposomal amphotericin-B (AmBisome) for treatment of cutaneous widespread candidosis in an infant with methylmalonic acidaemia.
In a 10-week-old infant with vitamin B12-unresponsive methylmalonic acidaemia, cutaneous candidosis (Candida albicans) progressed rapidly despite topical antifungal treatment. After 1 week of intravenous therapy with liposomal amphotericin-B (AmBisome) the dermatitis disappeared completely and blood cultures were sterile. No side-effects were observed. This is one of the first experiences in the treatment of infants with this new antifungal agent.
Stöckler
S
S
Department of Paediatrics, University of Graz, Austria.
Lackner
H
H
Ginter
G
G
Schwinger
W
W
Plecko
B
B
Müller
W
W
D000592:Amino Acid Metabolism, Inborn Errors / Q000150:complications*; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D002179:Candidiasis, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D008297:Male; D008764:Methylmalonic Acid / Q000097:blood*; D012867:Skin / Q000473:pathology
C068538:liposomal amphotericin B; D000666:Amphotericin B; D008764:Methylmalonic Acid